ARCHIVES

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

This article is from The Cancer Letter archive.

Vol. 13 No. 15 | April 10, 1987

Download PDF Visit The Full Archive

Related Articles

U.S., Canada Begin ExCel Trial To Evaluate Aromasin For Breast Cancer Prevention

April 29, 2005

Seattle Cancer Care Alliance Marks its 10th Anniversary—January 2011

June 28, 2021

DCBD Concepts Approved

November 8, 1985

Conferees Set NIH Funding At $30 Billion.

November 2, 2007

Toxic Substance Act Would Affect Cancer Program

March 21, 1975

Sequestration Delayed For Two Months While Congress Debates Debt and Budgets

January 4, 2013